S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

$17.51
+0.14 (+0.81%)
(As of 03/27/2024 ET)
Today's Range
$17.14
$18.02
50-Day Range
$17.09
$20.35
52-Week Range
$10.93
$30.30
Volume
707,704 shs
Average Volume
1.17 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.60

Viridian Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
109.0% Upside
$36.60 Price Target
Short Interest
Bearish
12.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Viridian Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.39) to ($4.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.65 out of 5 stars

Medical Sector

647th out of 939 stocks

Medical Laboratories Industry

15th out of 19 stocks

VRDN stock logo

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

VRDN Stock Price History

VRDN Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Unveiling 4 Analyst Insights On Viridian Therapeutics
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
VRDN Sep 2024 20.000 put
VRDN Apr 2024 20.000 put
Viridian Therapeutics GAAP EPS of -$1.35
VRDN Mar 2024 30.000 put
See More Headlines
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VRDN
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.60
High Stock Price Target
$46.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+109.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-237,730,000.00
Net Margins
-75,711.48%
Pretax Margin
-75,711.46%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$4.48 per share

Miscellaneous

Free Float
61,870,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
1.08
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Stephen F. Mahoney J.D. (Age 52)
    MBA, CEO, President & Director
  • Dr. Eric N. Olson Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D. (Age 79)
    Ph.D., Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers Ph.D. (Age 84)
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe Bedian Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Seth Harmon
    Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
  • Mr. Thomas W. Beetham J.D. (Age 54)
    MBA, Chief Operating Officer
  • Ms. Jennifer Tousignant J.D.
    Chief Legal Officer
  • Mr. John A. Jordan
    Vice President of Investor Relations & Corporate Communications
  • Mr. Anthony Casicano (Age 47)
    Chief Commercial Officer

VRDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings
or view top-rated stocks.

What is Viridian Therapeutics' stock price target for 2024?

10 brokerages have issued 12-month price objectives for Viridian Therapeutics' shares. Their VRDN share price targets range from $25.00 to $46.00. On average, they expect the company's stock price to reach $36.60 in the next twelve months. This suggests a possible upside of 109.0% from the stock's current price.
View analysts price targets for VRDN
or view top-rated stocks among Wall Street analysts.

How have VRDN shares performed in 2024?

Viridian Therapeutics' stock was trading at $21.78 at the beginning of 2024. Since then, VRDN shares have decreased by 19.6% and is now trading at $17.51.
View the best growth stocks for 2024 here
.

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRDN earnings forecast
.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.37. The firm earned $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. The business's revenue for the quarter was down 31.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.13) earnings per share.

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.71%), Vanguard Group Inc. (4.78%), Commodore Capital LP (3.66%), Perceptive Advisors LLC (3.29%), Vestal Point Capital LP (1.90%) and Octagon Capital Advisors LP (1.18%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers.
View institutional ownership trends
.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRDN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners